Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data.

[1]  Deepak L. Bhatt,et al.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. , 2014, European heart journal.

[2]  Deepak L. Bhatt,et al.  The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. , 2013, Cardiovascular therapeutics.

[3]  J. Shaw,et al.  Diabetes Prevention and Treatment Strategies , 2013, Diabetes Care.

[4]  J. Heuzey.  Antithrombotic treatment of atrial fibrillation: New insights , 2012 .

[5]  G. Lip,et al.  Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  An international model to predict recurrent cardiovascular disease. , 2012, The American journal of medicine.

[7]  Deepak L. Bhatt,et al.  Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[8]  Warner M Mampuya,et al.  Cardiac rehabilitation past, present and future: an overview. , 2012, Cardiovascular diagnosis and therapy.

[9]  J. Beckman,et al.  Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004 , 2011, Circulation.

[10]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[11]  P. Scuffham,et al.  Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial , 2011, Journal of medical economics.

[12]  Deepak L. Bhatt,et al.  Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States , 2010, Circulation. Cardiovascular quality and outcomes.

[13]  Deepak L. Bhatt,et al.  One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. , 2010, The Canadian journal of cardiology.

[14]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[15]  Deepak L. Bhatt,et al.  Drug treatment and cost of cardiovascular disease in Australia. , 2009, Cardiovascular therapeutics.

[16]  Deepak L. Bhatt,et al.  Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. , 2008, American heart journal.

[17]  J. Shaw,et al.  Lifetime risk and projected population prevalence of diabetes , 2008, Diabetologia.

[18]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[19]  C. Reid,et al.  Australians at risk: management of cardiovascular risk factors in the REACH Registry. , 2008, Heart, lung & circulation.

[20]  Peter Lindgren,et al.  Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  G. Lamas,et al.  Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective , 2008, Journal of medical economics.

[22]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[23]  Deepak L. Bhatt,et al.  The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. , 2006, American heart journal.

[24]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[25]  G. Hankey,et al.  Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications , 2004, The Medical journal of Australia.

[26]  V. Fuster,et al.  Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. , 2004, European heart journal.

[27]  J. Dinet,et al.  The Comparative Medical Costs of Atherothrombotic Disease in European Countries , 2012, PharmacoEconomics.

[28]  Deepak L. Bhatt,et al.  Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease , 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[29]  N. Carrier,et al.  Protective Vascular Treatment of Patients with Peripheral Arterial Disease: Guideline Adherence According to Year, Age and Gender , 2010, Canadian journal of public health = Revue canadienne de sante publique.

[30]  Bruce Hollingsworth,et al.  The economic implications of treating atherothrombotic disease in Australia, from the government perspective. , 2010, Clinical therapeutics.

[31]  R. Califf,et al.  The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. , 2006, American heart journal.